Upstream Bio (NASDAQ:UPB) Cut to Strong Sell at Wall Street Zen

Wall Street Zen lowered shares of Upstream Bio (NASDAQ:UPB) from a sell rating to a strong sell rating in a research note issued to investors on Saturday.

Several other analysts have also commented on the stock. HC Wainwright began coverage on shares of Upstream Bio in a research report on Wednesday, June 3rd. They set a “buy” rating and a $36.00 price target on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of Upstream Bio in a research report on Monday, August 3rd. Truist Financial dropped their target price on Upstream Bio to $25.00 and set a “buy” rating on the stock in a research report on Tuesday, August 11th. JPMorgan Chase & Co. lifted their price target on Upstream Bio from $8.00 to $9.00 and gave the company a “neutral” rating in a research note on Friday. Finally, Mizuho reduced their price target on Upstream Bio from $51.00 to $50.00 and set an “outperform” rating for the company in a report on Thursday, May 14th. Four analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $29.67.

Upstream Bio Trading Up 1.0%

Shares of UPB stock opened at $7.14 on Friday. Upstream Bio has a twelve month low of $5.85 and a twelve month high of $33.68. The stock has a market cap of $391.06 million, a P/E ratio of -2.46 and a beta of 1.26. The stock has a 50 day moving average of $6.82 and a 200 day moving average of $9.58.

Upstream Bio (NASDAQ:UPB) last released its quarterly earnings data on Tuesday, August 11th. The company reported ($0.73) EPS for the quarter, topping the consensus estimate of ($0.74) by $0.01. The business had revenue of $0.77 million for the quarter, compared to analyst estimates of $0.56 million. Upstream Bio had a negative return on equity of 48.40% and a negative net margin of 4,955.67%. On average, research analysts predict that Upstream Bio will post -2.87 earnings per share for the current fiscal year.

Institutional Trading of Upstream Bio

Several institutional investors have recently modified their holdings of the stock. Invesco Ltd. increased its stake in shares of Upstream Bio by 6.4% during the second quarter. Invesco Ltd. now owns 16,300 shares of the company’s stock worth $179,000 after purchasing an additional 985 shares in the last quarter. GF Fund Management CO. LTD. acquired a new position in shares of Upstream Bio during the 4th quarter worth about $29,000. Torren Management LLC purchased a new position in Upstream Bio in the 4th quarter valued at about $30,000. JPMorgan Chase & Co. lifted its stake in Upstream Bio by 8.4% in the 2nd quarter. JPMorgan Chase & Co. now owns 16,469 shares of the company’s stock valued at $181,000 after buying an additional 1,275 shares in the last quarter. Finally, Legal & General Group Plc boosted its holdings in Upstream Bio by 83.0% in the 2nd quarter. Legal & General Group Plc now owns 3,174 shares of the company’s stock worth $35,000 after buying an additional 1,440 shares during the last quarter.

Upstream Bio Company Profile

Upstream Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation prophylactic vaccines and immuno-oncology therapies. Leveraging a proprietary viral vector platform, the company aims to deliver optimized antigen payloads that stimulate robust and durable immune responses against both infectious diseases and cancer targets. Upstream Bio’s approach emphasizes safety, manufacturability and potential for rapid scale-up to address emerging public health challenges.

The company’s research and development pipeline includes multiple viral vector-based candidates in early clinical and preclinical stages.